IOFINA PLC (IOF) — Investment Research Note

Executive summary

Iofina is the second-largest iodine producer in North America, extracting iodine from oil & gas produced brine water in Oklahoma (and now the Permian Basin) via its proprietary WET® IOsorb® technology, with a vertically integrated specialty halogen chemicals business in Kentucky. Over the past five years the Group has transformed from a highly leveraged, barely-profitable AIM company into a cash-generative growth story: revenue has risen from $29.7m (2020) to $66.5m (2025) and net debt of $8.9m has flipped to net cash of $7.2m at H1 2026, with crystalline iodine production nearly doubling from 324MT to a run-rate approaching 1,000MT. The single most important valuation issue today is whether the market is correctly pricing the step-change from IO#12 (Permian, commissioning Q3 2026, +170-220MT/yr) and IO#13/14 (both operational H1 2027) that put Iofina on a credible path to 2,000MT/yr — roughly 5% of global iodine supply.

Fair value estimate

Fair value range: 48p – 70p per share (implied market cap £92m – £134m)

• Methodology: forward EV/EBITDA cross-checked against DCF.
• Key assumptions: 2026 full-year adj EBITDA of $14-16m (annualising H1 run-rate of $6.6m plus IO#12 part-year), 2027 EBITDA of $18-22m as IO#12 delivers a full year and IO#13/14 ramp. Target EV/EBITDA 7-8x (specialty chemicals mid-range), iodine prices held flat at ~$74/kg, USD/GBP 1.34.
• Mid-point: ~58p / £112m, implying ~14% upside to the current 51p / £97.8m.
• Current market cap: £97.8m → within the lower-middle of the range; share price has already more than doubled over 12 months (from 23p in Oct 2025) market data.

Sector context

• ICB classification confirmed: Basic Materials / Chemicals / Specialty Chemicals. More specifically, iodine is a specialty industrial mineral/halogen chemistry niche.
• Quality vs. peers: balance sheet quality is above typical sector peers (net cash, clean audit); growth is above typical chemicals peers; margins (18% EBITDA margin 2025) are in line with specialty chemicals.
• Listed peers: SQM (Chilean, world's largest iodine producer, but also lithium/potash — much larger, more diversified); Mitsubishi Chemical/ISE Chemicals (Japan, part of larger conglomerates); no pure-play small-cap peer, which gives Iofina scarcity value for iodine thematic exposure.

Investment thesis

1. Capacity-doubling pipeline on a cost-advantaged technology base — IO#12 (Permian, ~200MT/yr at $8.8m capex) plus IO#13/14 in H1 2027 take production from 750MT to a credible 1,500MT+ by end-2027, en route to the stated 2,000MT target. Each plant is relatively capital-light ($5-9m) with payback inside 2-3 years at current iodine prices 2026-04 final results, 2026-09 interim.
2. Robust iodine market pricing a persistent supply-demand gap — Spot iodine has held above $70/kg for three years, with structural demand drivers (X-ray contrast media growth, perovskite solar cell adoption from 2024+, next-generation CF3I-based refrigerants) that Iofina Chemical is positioned to capture via vertical integration. Average realised price was $74.69/kg in H1 2026 2026-09 interim.
3. Fortress balance sheet funds growth from cash flow — Net cash of $7.2m at H1 2026 with $5.8m H1 capex self-funded; $10m undrawn project loan facility. 2026 H1 Adj EBITDA +103% YoY demonstrates operational leverage is converting into cash and reinvestment capacity without equity dilution 2026-09 interim.

Key risks

1. Brine supply dependence on third-party oil & gas operators — the business cannot exist without partner wells producing iodide-rich brine. Any reduction in oil & gas drilling or operator capital discipline (as seen in 2024 when brine supply dipped) directly compresses iodine production. The Western Midstream Permian partnership diversifies but doesn't eliminate this 2026-04 final results — Principal Risks.
2. Iodine price concentration risk — ~80% of revenue is iodine-linked. Chilean producer SQM is building a seawater pipeline project (completing 2026) and Cosayach's Bull Mine is likely to add supply late-2026/2027. A reversion to historical $40-50/kg prices would halve current EBITDA. Prices have held firm but there is no hedge 2026-04 final results — Iodine Market Outlook.
3. Execution risk on three concurrent plant builds — IO#13 and IO#14 building simultaneously is unprecedented for Iofina; the previous IO#9 build in 2023 ran meaningfully over the $4m budget to $5.8m. Any delays or cost overruns compress the 2027 EBITDA ramp that current valuation is anticipating 2026-09 interim, historical commentary on IO#9.

Operating leverage

Iofina shows genuine operating leverage of the capital-intensive-industrial variety, well-evidenced in 2026 H1 numbers: revenue grew 7% ($29.2m → $31.3m) but gross profit grew 62% ($6.3m → $10.2m) and Adjusted EBITDA grew 103% ($3.3m → $6.6m). Management explicitly describes this: "the key factor in the percentage of sales improvement being the better-than-expected level of production applied to plant operating costs, which are largely fixed" 2026-09 interim. Each IOsorb® plant has largely fixed labour, maintenance, and depreciation; incremental iodine extracted drops at roughly $45-50/kg contribution margin (iodine selling at $75/kg minus ~$25-30/kg marginal chemicals/freight). A 10-20% revenue beat from faster IO#12/13/14 ramp or stronger iodine pricing would plausibly add 40-60% to operating profit at this scale. The 2026 inflection — EBITDA margin rising from 11% to 21% H1-on-H1 — illustrates the model exactly. Not a software-like leverage profile (variable raw material costs are real), but materially above typical industrials.

Value-trap signals

• None identified — revenue has grown eight consecutive years, net cash is strengthening, the audit is unqualified, there is no customer concentration above 17%, no related-party flags beyond fully disclosed intra-group transactions, no going-concern caveats, no dividend to cut, and no decline-industry characteristics. The business has executed consistently and transparently.

Earnings vs. expectations

Across the five-year window the pattern is: FY2021 record results (first post-pandemic recovery) beat; FY2022 beat materially on iodine price surge; FY2023 soft miss on EBITDA with brine renegotiation and inflation (though revenues met); FY2024 miss again on EBITDA (brine supply disruption, higher fees to one partner — Group explicitly flagged "no less than $8.5-9m" vs $7.6m delivered); FY2025 beat on both revenue and EBITDA ($66.5m / $11.8m vs expectations of record year); H1 2026 and recent trading updates have shown clear beats. The pattern is: beats when iodine price and brine supply cooperate, misses when weather or partner capex cycles disrupt production. Over the full cycle: roughly in-line to modestly beat, with execution clearly improving over the last 18 months.

Conviction

Conviction: 3 (moderate). Anchoring factors: (a) five years of clean, consistent, audited financials with transparent segmental disclosure; (b) a specific and already-funded capacity expansion pipeline (IO#12 contracted and under construction, IO#13/14 signed) that makes 2027 projections concrete rather than speculative; (c) stable iodine price regime for 3+ years supporting the margin assumption. Limiting factors: (a) iodine price is a commodity exposure outside management control, and new Chilean supply in 2026-2027 creates genuine downside tail; (b) 2027 EBITDA depends on three plants ramping simultaneously, which has not been attempted before. A different methodology (DCF with lower discount rate) could land 10-15p higher; a near-term iodine price shock could land 15-20p lower.

Driver scoring commentary

This is fundamentally a specialty industrial minerals / chemicals business with no meaningful AI-receiver exposure. The one tangential link — Iofina Chemical sells methyl fluoride as a semiconductor etchant gas — represents <10% of revenue and is not growing as a function of AI buildout. Perovskite solar cells and CF3I refrigerants are promising long-tail demand drivers but are not AI-related. For the AI-focused investor profile, this is clearly off-thesis despite being a quality small-cap in its own right.